Alzprotect
Biopharmaceutical company which develop new bioactive molecules for the treatment of neurodegenerative diseases.
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Alzprotect is a biopharmaceutical company focused on the development of drug candidates aimed at treating neurodegenerative diseases such as Alzheimer's disease (AD) and tauopathies, including Progressive Supranuclear Palsy (PSP). The company operates in the healthcare and pharmaceutical market, targeting patients suffering from these debilitating conditions. Alzprotect's business model revolves around the discovery, development, and clinical trials of its drug candidates. Revenue is generated through the successful progression of these drugs through clinical trials, leading to potential partnerships, licensing agreements, and eventual commercialization. The company serves a critical need in the medical community by addressing diseases with significant unmet medical needs.
Keywords: biopharmaceutical, drug development, neurodegenerative diseases, Alzheimer's, tauopathies, clinical trials, healthcare, pharmaceutical, Progressive Supranuclear Palsy, medical research.